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Abstract
From the report by Connors and coworkers in 1996 until now,
much effort has been directed at demonstrating the safety and/or
effectiveness of strategies based on pulmonary artery catheter
(PAC) data. Although studies have failed to demonstrate a clear
benefit of PAC use, neither have any corroborated the initial report
of PAC-induced mortality. With this in mind, it is important to clarify
the indications for PAC, taking into account the development of
new technologies to measure cardiac output and stroke volume.
The present review focuses on safety and effectiveness data, with
a special focus on reasonable indications for PAC use in the
intensive care unit. The PAC has evolved since its initial
presentation, and it now offers numerous parameters in addition to
cardiac output and pressure measurement, such as mixed oxygen
saturation and right ventricular ejection fraction. Because many
techniques may be used to measure cardiac output, the indications
for PAC use have become founded on other parameters that are
useful in more specific situations, essentially involving the right
circulation.
Introduction
The pulmonary artery catheter (PAC) is a monitoring device
that is still largely used in the intensive care unit (ICU).
However, the context surrounding use of this invasive
monitoring system has evolved over the past decade. The
motivation to find noninvasive or mildly invasive surrogate
techniques has been partially successful; echocardiography,
Doppler and pulse contour techniques have been proposed
as alternatives. The famous report from Connors and
coworkers [1] created turmoil among intensivists and
resulted in clinical trials to test the potential benefit of PAC
use. That report used a propensity score as a technique to
compare patients with versus those without PAC placement.
In a mixed population of medical and surgical ICU patients,
Connors and coworkers found that increased mortality,
length of stay and costs were associated with use of a PAC.
In addition, many have claimed that there are no good data to
support the use of the PAC because no study has
demonstrated an outcome benefit in patients undergoing a
therapeutic strategy based on PAC data.
Before reviewing the data available in order to define the type
of patients who may benefit from PAC use, some important
issues must be borne in mind. First, the prognosis of severely
ill patients cannot be improved by catheter insertion per se.
Second, performing randomized controlled studies in
homogeneous, specific groups of patients is impracticable
because of marked overlap between the different syndromes
or diseases. For example, acute respiratory distress
syndrome (ARDS) is most often related to severe lung
infection with sepsis or septic shock.
The issues important for intensivists are embodied by the
following three questions. Does PAC insertion carry a
significant risk of complications? Can the data provided by
the PAC improve outcomes in severely ill patients? Finally, do
we have data to improve our definition of the type of patients
or diseases for which PAC may improve quality of care and
outcomes in the ICU?
Risk for complications
Previous studies reported a series of complications related to
PAC insertion, including arrhythmia, vein thrombosis, infection,
pulmonary artery (PA) rupture and intracardiac lesions [2].
More recent data did not provide evidence for either a high
risk for complications or a link between PAC use and death.
The ESCAPE (Evaluation Study of Congestive Heart Failure
and Pulmonary Artery Catheterization Effectiveness) study [3]
found that approximately 4% of patients undergoing PAC
placement had complications, including cardiac arrest and
infection, but there were no PAC-related deaths. A recent
French study [4] reported no cases of pulmonary embolism,
but 2.8% of patients suffered PAC-related infections.
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Sandham and coworkers [5] reported a higher incidence of
pulmonary embolism in the PAC group than in the control
group.
If it is presumed that any risk associated with PAC placement
results from the invasiveness of the technique and not the
device  per se, then the PAC in itself cannot influence
prognosis directly. Rather, justification for PAC insertion must
be based on better strategies of care in complex patients
resulting from its use, in turn yielding better outcomes. No
study evaluating PAC-induced changes in management
strategy and resulting outcomes has yet been reported. In the
absence of such data, it is a challenge to define the proper
indications for PAC use. The list of indications in the general
ICU were based on expert opinion or nonrandomized trials,
and pertain to patients with severe cardiac failure, severe
sepsis or septic shock, or acute respiratory failure. Develop-
ments in PAC technology allowed additional variables to be
evaluated that changed the indications, mainly focusing on
global tissue oxygenation or right-sided problems.
Indications for use of the pulmonary artery
catheter
Since its introduction, the PAC has been used to characterize
circulatory failure by measuring cardiac output, right and left
filling pressures, and more recently mixed venous oxygen
saturation (a global index of tissue oxygenation); and to
evaluate the effects of haemodynamic therapeutic strategies.
Studies conducted in specific patient populations, such as
those who have undergone cardiac surgery or organ
transplantation, are excluded from the present review.
Following the report by Connors and coworkers [1], many
investigators began to evaluate whether long-term use of the
PAC may affect morbidity or mortality in critically ill patients.
In a retrospective study conducted in more than 10,000
patients included in a critical care database maintained by the
Society of Critical Care Medicine (SCCM) [6], independent
factors linked to PAC use were the setting of a surgical ICU
and (for patients of white race) having a private medical
insurance contract. Importantly, the presence in the ICU of a
full-time critical care physician was associated with reduced
PAC use [7].
In 2000, a meta-analysis of the effectiveness of the PAC was
conducted [8]. The authors searched the Medline database,
from 1970 to 1996, for reports including the following terms
in the title: ‘pulmonary artery catheterization’ and ‘Swan-Ganz
catheterization’. The results were restricted to those on
‘effectiveness’ and ‘usefulness’. A total of 1610 patients
included in 12 trials were analyzed. The results showed that
there was lower mortality in the PAC group, with a relative
risk ratio of 0.8 (corresponding to P < 0.02). Although such
meta-analyses have certain limitations, this observation at
least confirmed the safety of PAC use in ICU patients and
suggested potential benefit.
In a prospective, descriptive cohort study, Mimoz and
coworkers [9] demonstrated a change in therapy after
insertion of a PAC in patients with circulatory shock who did
not respond to standard therapy. This therapeutic
modification was statistically associated with better morbidity,
and this was independent of the other outcomes evaluated.
Recently, a European observational study on PAC use and
outcomes in the ICU was reported [10]. Compared with
controlled trials, observational studies have certain advan-
tages in that they avoid selection bias and problems relating
to physician compliance, among others. The study carefully
considered and corrected for all possible confounding
variables. The authors adjusted for confounding variables
between the PAC and non-PAC populations using multi-
variate regression analysis and propensity score case
matching. Although ICU and hospital mortality rates were
higher in patients undergoing PAC placement, its use was
not an independent risk factor for 60-day mortality (multi-
variate analysis). In 453 propensity-matched pairs of ICU
patients with or without PAC placement, ICU and hospital
mortality rates were similar. Survival to 60 days was similar
between the two matched groups, allowing the authors to
conclude that PAC use was not associated with increased
mortality in this heterogeneous population.
Five randomized trials (including two reported in 2005)
examined the effectiveness of PAC use in critically ill
populations [3,4,11-13]. None of these trials demonstrated
an impact of PAC use on the outcome variables assessed.
We summarize the results of these trials below, focusing on
patient populations who may benefit from PAC use where
possible. Patients enrolled in these trials suffered from
cardiovascular disease, severe sepsis or septic shock, and
ARDS or acute lung injury (ALI).
Rhodes and coworkers [12] randomized 201 critically ill
patients to a PAC group (n = 95) or a control group
(n = 106). Survival to 28 days, intensive care and hospital
lengths of stay, and organ dysfunction were compared on an
intent-to-treat basis. There was no significant difference in
mortality between the PAC group and the control group,
allowing the authors to conclude that PAC use is not
associated with increased mortality. Richard and colleagues
[4] conducted a multicentre, randomized controlled study of
676 patients (335 underwent PAC placement and 341 did
not) who fulfilled criteria for shock or ARDS, or both. Using
mortality at 28 days as the primary end-point, they found no
significant differences in mortality between the two groups.
They concluded that clinical management involving early use
of a PAC did not significantly affect mortality or morbidity.
In the recent PAC-Man (Pulmonary Artery Catheters in
Patient Management) study [13], Harvey and coworkers
randomized 1041 patients from 65 UK ICUs to management
with (n = 519) or without (n = 522) a PAC. Again their resultsPage 3 of 6
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indicated no difference in hospital mortality between critically ill
patients managed with or without a PAC. Although
complications associated with PAC insertion were noted in 9%,
none of these were fatal. The authors concluded that there was
no clear evidence of benefit or harm resulting from management
of critically ill patients with a PAC. They highlighted the need for
efficacy studies based on management protocols involving PAC
use in specific groups of patients, in order to identify whose who
could benefit from management using a PAC.
Has any benefit from PAC use been demonstrated in severe
heart failure? Congestive heart failure is among the most
common, persistent and deadly cardiovascular diseases.
PAC use in this condition varies markedly between centres,
suggesting a lack of consensus on the safety and utility of
this device in congestive heart failure [14]. The recent
ESCAPE study [3] was conducted to test whether PAC use
is safe and can improve the clinical outcome in patients with
severe symptomatic and recurrent heart failure. In the
ESCAPE study, a randomized controlled trial including 433
patients, therapy was guided either by clinical assessment
and a PAC or by clinical assessment alone. The target in both
groups was resolution of clinical congestion, with additional
PAC targets of a pulmonary capillary wedge pressure of
15 mmHg and a right atrial pressure of 8 mmHg. The primary
end-point was days alive out of the hospital over the first
6 months, with secondary end-points of exercise, quality of
life, and biochemical and echocardiographic changes. The
use of the PAC did not significantly affect the primary end-
point. However, the authors did observe a trend toward
greater improvement in exercise capacity and quality of life in
the PAC group. In conclusion, addition of a PAC did not
affect mortality or hospitalization.
Practical guidelines for use of the pulmonary
artery catheter
None of the present studies found any positive impact of PAC
use on outcome variables. However, prospective, randomized
studies in which the PAC was used as part of a management
algorithm have shown improved outcomes in high-risk surgical
patients [15,16], although it should be noted that these
studies did not provide an explicit protocol for care based on
PAC-generated data. Assessment of a monitoring technology
in a vacuum is unlikely to demonstrate benefit. Efficacy (PAC
linked to explicit treatment protocols dictated by the study)
cannot therefore be assessed at present.
What, then, is the evidence regarding the broader issue of
PAC use in the ICU? The data collected to date do not
support routine use of the PAC in any patient group, justifying
withdrawal of the PAC from routine use. The only trial as yet
to evaluate a strategy guided by PAC use in patients with
ARDS was recently completed (results are yet to be
published) [17]. The trial compared a ‘fluid conservative’
approach with a ‘fluid liberal’ strategy. If a positive result
attributable to PAC is demonstrated, then a specific ‘niche’
for the technology may remain in critical care. If the results
demonstrate no benefit, then PAC use will become limited to
rescue therapy in a small number of select patients. Among
these, complex cases associated more with right than with
left ventricular failure within the context of ARDS secondary
to severe sepsis or septic shock may benefit from guidance
of therapy with PAC-derived data.
The previous consensus conference on PAC use must then
be revisited in light of the most recently published trials and
meta-analyses. In critical care and/or perioperative settings,
two major reports must be considered: the consensus
conference from the SCCM [6] and the guidelines from the
American Society of Anesthesiologists [2]. The recent
publication of guidelines for diagnosis and treatment of
cardiac failure provides an opportunity to define better the
position of PAC use in this setting as well [18].
Indications for pulmonary artery catheter use in cardiac
failure
Myocardial infarction complicated by cardiogenic shock or
progressive hypotension is a class I indication for PAC use in
the formulated American College of Cardiology/American
Heart Association guidelines [19]. This recommendation is also
included in the PAC consensus conference convened by the
SCCM in 1997 [6]. It is based on expert opinion, and there is
no conclusive proof that PAC use improves outcomes in this
patient population [6]. The SCCM consensus conference also
indicated that PAC use was appropriate in patients with
congestive heart failure refractory to empirical therapy.
The European Society of Cardiology guidelines [18]
published in 2005 insist that invasive monitoring of patients
with acute heart failure (AHF) should be initiated as soon as
possible after they arrive at the emergency unit, concurrent
with ongoing diagnostic measures to determine the primary
aetiology. Those guidelines based on expert opinion also
indicate that although PAC insertion for diagnosis in AHF is
usually unnecessary, it could be used to distinguish between
a cardiogenic and a noncardiogenic mechanism in complex
patients with concurrent cardiac and pulmonary disease. The
use of PAC is a class IIb recommendation (level C evidence)
in haemodynamically unstable patients who are not
responding in a predictable manner to traditional treatment,
and in patients with a combination of congestion and hypo-
perfusion. In these cases, the PAC is inserted to ensure
optimal fluid loading of the ventricles and to guide vasoactive
therapies and inotropic agents.
It is recommended that, in cardiogenic shock and prolonged
severe low output syndrome, the mixed venous oxygen
saturation from the PA be measured and maintained above
65% in patients with AHF [6].
Experts have stated that direct measurement of haemo-
dynamics can be helpful in patients for whom the physical
Available online http://ccforum.com/content/10/S3/S7examination with symptoms is unrevealing or discordant. It
may be particularly useful for determining the contribution of
heart failure to a complex clinical picture, such as sepsis,
acute renal failure, or acute coronary syndrome, in the setting
of chronic heart failure. Another common setting in which
PAC insertion may be helpful is in the evaluation of dyspnoea
and elevated right heart pressures in patients with
concomitant pulmonary and cardiac disease.
Concerning right heart failure, catheterization of the PA is
more invasive than echocardiography, but it is useful in
evaluating right ventricular function and in confirming the
presence of right ventricular failure in patients in the ICU [20].
Indications for severe sepsis or septic shock
Based largely on expert opinion, the consensus conference
of 1997 [6] concluded that PAC use may be appropriate in
patients with septic shock who are unresponsive to early
resuscitative measures. Maintenance of normal haemo-
dynamics in this group appeared to be the most appropriate
goal. Research is needed to determine the proper role of the
PAC in patients with sepsis or sepsis shock.
In 2004, the American College of Critical Care Medicine
reported an update to their recommendations on practice
parameters for haemodynamic support of sepsis in adult
patients [21]. The authors of the report highlighted the
principles that clinicians using haemodynamic therapies
should define specific goals and end-points, titrate therapies
to achieve these end-points, and evaluate the results of their
interventions on an ongoing basis by monitoring a combina-
tion of variables that reflect global and regional perfusion and,
if possible, the microcirculation. The assessment of cardiac
filling pressures may require a central venous catheter or a
PAC. With a level D recommendation, invasive haemo-
dynamic monitoring should be considered in those patients
who do not respond to initial resuscitative efforts; this
monitoring should be combined with fluid infusion titrated to a
goal-directed level of filling pressure associated with the
greatest increase in cardiac output and stroke volume. For
most patients, this will correspond to a PA occlusion
pressure in the 12-15 mmHg range.
It is likely that the question of whether the PAC offers
potential benefit for patients with septic shock will only be
answered by a randomized, prospective trial in which both
education on proper measurements and consensus treatment
protocols are used.
In a case-control study, nested within a prospective cohort
study, Yu and coworkers [22] examined the relationship
between PAC use and patient outcomes, including mortality
rates and resource utilization, in patients with severe sepsis in
eight academic medical centres. They stratified a random
sample of 1010 adult admissions with severe sepsis. Among
patients with severe sepsis, they found that PAC placement
was not associated with a change in mortality rate or
resource utilization, although there was a small nonsignificant
trend toward lower resource utilization in the PAC group.
However, PAC use was associated with an increased risk for
renal failure within 28 days after sepsis onset but not with
increased risks for other complications, including ARDS,
shock, disseminated intravascular coagulation, liver failure, or
central nervous dysfunction.
Indications in acute lung injury/acute respiratory
distress syndrome
The 1997 consensus conference convened by the SCCM [6]
indicated that the optimal role of the PAC as a diagnostic and
monitoring device in different types of respiratory failure has
not been clearly defined. Research is needed to determine
the role of the PAC in very carefully defined groups of
patients with respiratory failure. The trial reported by Richard
and coworkers [4] failed to find any benefit for PAC use in the
subgroup of patients with ARDS.
In their retrospective study, Connors and colleagues [1]
found an increased relative risk for death in the 1789 patients
who had ARDS. The authors provided the following
explanations for the observed lack of benefit. First, direct
catheter-related complications during PAC use, such as
catheter-related sepsis, might have outweighed any potential
benefit of PAC placement. Second, PAC data might have
been improperly obtained, leading to spurious haemodynamic
profiles and resulting treatment. Finally, even if PAC data had
been carefully obtained, the data may have been inaccurate
and imprecise (for example, intravascular pressure values do
not represent the transmural values, the only one able to
inform on heart filling; tricuspid regurgitation may give
inaccurate cardiac output measurements; mixed SvO2 might
be artificially high in the presence of left to right shunt. These
conditions may change the accuracy even though the
technique for measurement is good). Another explanation for
these results was given by Richard and coworkers [4], who
hypothesized that the study by Connors and colleagues
might have overestimated the mortality in the PAC group
because of limitations associated with retrospective matching
of patients. Connors and colleagues chose to use a
propensity score, but this score did not take into account the
intensity of treatment used to sustain haemodynamics. This
approach could have masked a greater severity of illness in
the patients undergoing PAC placement. In any case, all of
these possibilities will have to be evaluated in a prospective,
randomized controlled trial.
Interestingly, a study addressed predictors of mortality in
acute respiratory failure [23]. The authors examined a retro-
spective cohort study of consecutive ARDS patients admitted
to two medical ICUs of tertiary care hospitals in whom two
different approaches to haemodynamic monitoring were
used: PAC on demand and no use of PAC. The study
evaluated risk factors for death and the influence of PAC,
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factor, in 98 patients in whom the delay between onset of
ARDS, use of vasopressors and PAC placement did not
exceed 48 hours. The authors identified only two indepen-
dent predictors of death: an extrapulmonary cause of ARDS
and need for maximal haemodynamic support with
epinephrine/norepinephrine to control circulatory failure. The
results did not permit detection of either a benefit or an
adverse effect of invasive monitoring through the PAC. In
2003, Richard and coworkers [4] found no difference in
morbidity and mortality at both 14 and 28 days.
Conclusion
PA catheterization is mostly used to define the mechanism of
circulatory failure and to optimize patient management. This
remains based on expert opinion, and no data exist from trials
using mortality or other ‘hard’ outcome measures.
Since its introduction in 1970 [24], the PAC has changed the
approach to haemodynamic management of patients. In
recent years, PAC use has become a subject of controversy.
Critics have highlighted difficulties with PAC insertion, use
and data interpretation, and complications associated with
the device. With respect to PAC-related serious effects, such
as death, the rate is probably under 0.1% [1,25].
Pinsky and Vincent, in a recent perspective [26], pointed out
that the problem not only pertains to PAC use or non-use or
to interpretation of PAC data; rather, they noted that no
monitoring device will improve outcomes unless it is coupled
with a specific treatment plan that is known to improve
outcome.
Indeed, how physicians respond to haemodynamic data is a
major issue when evaluating PAC use in management of ICU
patients. Jain and coworkers [27] conducted a cross-
sectional survey of board-certified intensivists to address this
issue. A survey questionnaire containing three medical
intensive care clinical vignettes was mailed to critical care
physicians. Each vignette contained PAC data and a half of
the surveys contained echocardiographic information. Every
respondent was asked to select one of six interventions for
each vignette. The authors received 126 responses and they
identified significant heterogeneity in selecting interventions
based on PAC data among intensivists; the presence of
echocardiographic results changed the intervention selected
but did not reduced the heterogeneity.
In this context, in 2000 the US National Heart, Lung and
Blood Institute and US Food and Drug Administration [14]
published a workshop report. This report concluded that
there is a need for collaborative education of physicians and
nurses in performing, obtaining and interpreting information
derived from PAC use. It also recommended that PAC use in
the following areas should be given high priority for clinical
trials: persistent/refractory congestive heart failure, ARDS,
severe sepsis and septic shock, and low-risk coronary artery
bypass graft surgery.
There remains a need for prospective randomized trials
studying the effectiveness of the PAC, including a strict
treatment protocol standardizing therapeutic choices
according to PAC derived variables.
A prospective, randomized, multicentre trial of ‘fluid
conservative’ versus ‘fluid liberal’ management of ALI and
ARDS was recently completed, and the protocol is available
on the internet [17]. This trial will provide real information on
the efficacy of the PAC in ICU patients, because strategies
will be evaluated comparing use of PAC variables versus
clinical evaluation plus other haemodynamic tools.
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